Protagonist Therapeutics Inc banner

Protagonist Therapeutics Inc
NASDAQ:PTGX

Watchlist Manager
Protagonist Therapeutics Inc Logo
Protagonist Therapeutics Inc
NASDAQ:PTGX
Watchlist
Price: 105.98 USD 2.17% Market Closed
Market Cap: $6.8B

Protagonist Therapeutics Inc
Total Current Assets

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Protagonist Therapeutics Inc
Total Current Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Assets CAGR 3Y CAGR 5Y CAGR 10Y
Protagonist Therapeutics Inc
NASDAQ:PTGX
Total Current Assets
$577.6m
CAGR 3-Years
33%
CAGR 5-Years
13%
CAGR 10-Years
45%
Abbvie Inc
NYSE:ABBV
Total Current Assets
$29.1B
CAGR 3-Years
1%
CAGR 5-Years
4%
CAGR 10-Years
6%
Gilead Sciences Inc
NASDAQ:GILD
Total Current Assets
$18.3B
CAGR 3-Years
8%
CAGR 5-Years
3%
CAGR 10-Years
-3%
Amgen Inc
NASDAQ:AMGN
Total Current Assets
$29.1B
CAGR 3-Years
9%
CAGR 5-Years
7%
CAGR 10-Years
-3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Total Current Assets
$11.2B
CAGR 3-Years
-5%
CAGR 5-Years
7%
CAGR 10-Years
23%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Total Current Assets
$18B
CAGR 3-Years
4%
CAGR 5-Years
13%
CAGR 10-Years
20%
No Stocks Found

Protagonist Therapeutics Inc
Glance View

Market Cap
6.8B USD
Industry
Biotechnology

Protagonist Therapeutics Inc. stands as a pioneering player in the biopharmaceutical landscape, diligently orchestrating the journey from scientific discovery to therapeutic breakthroughs. Established with the vision to exploit the therapeutic potential of peptides, the company has carved a niche for itself by focusing on innovative peptide-based drug discovery and development. Their proprietary technology platform is designed to genetically engineer and optimize peptides aimed at treating a spectrum of diseases, notably in areas of unmet medical needs such as autoimmune conditions and rare genetic disorders. The fusion of cutting-edge biotechnology and seasoned expertise enables Protagonist to transform promising scientific concepts into viable medicines, paving the way for advancements in patient treatment options. Fueling its growth and revenue potential, Protagonist Therapeutics operates primarily through partnerships and collaborative alliances, as well as progressing its proprietary pipeline. By leveraging strategic collaborations with established pharmaceutical giants, the company garners funding, technological insights, and broader developmental capabilities. This collaborative synergy not only bolsters their research endeavors but also hastens the clinical development and eventual commercialization of their pipeline products. Their ability to secure partnerships and effectively progress their drug candidates through various clinical stages is critical to their financial model, converting scientific innovation into shareholder value and societal impact. The company continues to navigate the complexities of drug development with a steadfast focus on unlocking the therapeutic potential of peptides, aspiring to merge innovation with tangible health benefits.

PTGX Intrinsic Value
12.83 USD
Overvaluation 88%
Intrinsic Value
Price $105.98

See Also

What is Protagonist Therapeutics Inc's Total Current Assets?
Total Current Assets
577.6m USD

Based on the financial report for Dec 31, 2025, Protagonist Therapeutics Inc's Total Current Assets amounts to 577.6m USD.

What is Protagonist Therapeutics Inc's Total Current Assets growth rate?
Total Current Assets CAGR 10Y
45%

Over the last year, the Total Current Assets growth was -2%. The average annual Total Current Assets growth rates for Protagonist Therapeutics Inc have been 33% over the past three years , 13% over the past five years , and 45% over the past ten years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett